Passage BIO, Inc.

Passage BIO, Inc.

Biotechnology • Healthcare • Philadelphia, PA, United States • PASG (NCM)

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

267 866 0311 One Commerce Square, Philadelphia, PA 19103, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Passage Bio Announces 1-for-20 Reverse Stock Split - Yahoo Finance
Yahoo Finance • Jul 10
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire
GlobeNewswire • Nov 10
Lucid Capital Markets initiates Passage Bio stock with Buy rating - Investing.com
Investing.com • Nov 24
Passage Bio (NASDAQ: PASG) to join Guggenheim fireside chat Nov 12, 9:30 a.m. - Stock Titan
Stock Titan • Nov 5
Passage Bio Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance - Nasdaq
Nasdaq • Jul 10

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Passage BIO, Inc. had layoffs?
No layoff events have been recorded for Passage BIO, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Passage BIO, Inc. have?
Passage BIO, Inc. has approximately 60 employees.
What industry is Passage BIO, Inc. in?
Passage BIO, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Passage BIO, Inc. a publicly traded company?
Yes, Passage BIO, Inc. is publicly traded under the ticker symbol PASG on the NCM. The company has a market capitalization of approximately $0.03 billion.
Where is Passage BIO, Inc. headquartered?
Passage BIO, Inc. is headquartered in Philadelphia, PA, United States at One Commerce Square, Philadelphia, PA 19103, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.